NASHVILLE, Tenn., April 28, 2016 (GLOBE NEWSWIRE) -- Healthways (NASDAQ:HWAY) today announced financial results for the first quarter ended March 31, 2016.
First-Quarter 2016 Financial Highlights
- Revenues of $189.2 million compared with $189.9 million for the first quarter of 2015;
- Net loss of $14.2 million, or $0.39 per share, compared with a net loss of $2.9 million, or $0.08 per share, for the first quarter of 2015; and
- Adjusted net loss per share of $0.08 compared with adjusted net loss per share of $0.01 for the first quarter of 2015. The adjusted results for the first quarter of 2016 exclude $5.7 million of restructuring charges; $5.0 million for a deferred tax asset valuation allowance; $2.3 million of non-cash share-based compensation; $1.8 million of non-cash interest expense; and $0.4 million of CEO transition-related expenses. The adjusted results for the first quarter of 2015 exclude $2.4 million of non-cash share-based compensation and $1.7 million of non-cash interest expense.
|(In millions, except per-share data)|
|See pages 9-10 for a reconciliation of non-GAAP financial measures|
|Three Months Ended|
|Net (loss) income||(14.2||)||(2.9||)|
|Net (loss) income per share, GAAP basis||$||(0.39||)||$||(0.08||)|
|Non-cash interest expense per share||0.03||0.03|
|Restructuring charges per share||0.1||-|
|Deferred tax asset valuation allowance per share||0.14||-|
|CEO transition-related expenses per share||0.01||-|
|Non-cash share-based compensation per share||0.04||0.04|
|Adjusted net (loss) income per share1||$||(0.08||)||$||(0.01||)|
|1 Figures may not add due to rounding|
“We are very pleased with our first-quarter performance, which reflects encouraging market demand, strong execution by our team and supports our confidence in our financial guidance for the full year. Revenues were largely in line with last year. New business revenues offset the year-over-year revenue reduction of approximately $8 million related to The Hawai‘i Medical Service Association (HMSA) contract amendment and the sale of Navvis,” said Donato Tramuto, Healthways Chief Executive Officer. “We are also making excellent progress on our structural reorganization and cost rationalization plan (the “Plan”), which we expect to be complete by the end of the third quarter. In addition, we remain engaged in the strategic review of our business, and we expect to complete the review and communicate our conclusions before the end of the second quarter.”
Alfred Lumsdaine, Healthways Chief Financial and Chief Administrative Officer, added, “First-quarter restructuring charges of $5.7 million related to the Plan brought our cumulative costs incurred through the end of the quarter to $20.8 million of the approximately $25 million expected in total. We expect annual gross cost savings in 2017 in a range of $40 million to $45 million, with savings recognized in the first quarter of 2016 and accruing at an increasing pace during the year.
“During the quarter, we generated $11.8 million of adjusted EBITDA. As is our typical pattern, we begin the year with our lowest level of earnings as performance-based fee recognition is heavily weighted to the second half of the year. As is also typical, our new business and existing business have ramping revenue growth through the year. In addition, as previously discussed, we began restructuring-related investments in the Company during the first quarter. We are confident that this reinvestment in our business, which includes certain new resources, as well as incentive plans for our colleagues, will help to deliver performance improvements Company-wide. As previously discussed, the net savings from the Plan are expected to grow each quarter during 2016.
“We generated $7.4 million of cash flow from operations for the first quarter and incurred capital expenditures of $6.5 million. In addition, we reduced net debt by $2.2 million for the quarter and expect a net debt reduction of at least $30 million for full-year 2016. At the end of the first quarter, the Company’s ratio of total debt to EBITDA, as calculated under the amended credit facility, was just under 3.0.”
2016 Financial Guidance
Healthways today has affirmed its financial guidance for 2016, as follows:
- Adjusted for an aggregate year-over-year revenue reduction of $39 million from the HMSA contract amendment and the sale of Navvis, guidance for 2016 revenue is for a percentage growth rate in the low to middle single digits range.
- Beginning in 2016, the Company is excluding non-cash share-based compensation from adjusted EBITDA. Guidance for 2016 adjusted EBITDA, which also excludes restructuring charges and CEO transition-related expenses, is in a range of $85 million to $90 million, compared with adjusted EBITDA for 2015 of $80 million, which excluded non-cash share-based compensation, restructuring charges, joint venture investment impairment and related loss on the remaining investment commitment, CEO transition-related expenses and gain on the sale of Navvis.
- The Company expects to use its free cash flow to reduce its debt by at least $30 million at December 31, 2016, compared with December 31, 2015.
Healthways will hold a conference call to discuss this release today at 5:00 p.m. Eastern Time. Investors will have the opportunity to listen to the conference call live over the Internet by going to www.healthways.com and clicking Investors at least 15 minutes early to register, download and install any necessary audio software. Presentation materials related to the conference call may also be accessed by going to www.healthways.com and clicking Investors. For those who cannot listen to the live broadcast, a telephonic replay will be available for one week at 719-457-0820, code 1982993, and the replay will also be available on the Company’s web site for the next 12 months.
Safe Harbor Provisions
This press release contains forward-looking statements, including our guidance and financial expectations for future periods, which are based upon current expectations, involve a number of risks and uncertainties and are subject to the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. Those forward-looking statements include all statements that are not historical statements of fact and those regarding the intent, belief or expectations of the Company, including, without limitation, all statements regarding the Company’s future earnings and results of operations. Those forward-looking statements are subject to the finalization of the Company’s quarterly financial accounting procedures and may be affected by certain risks and uncertainties, including, but not limited to:
- the Company’s ability to estimate the costs associated with, and to implement and realize the anticipated benefits of, the structural reorganization and cost rationalization plan;
- the effectiveness of management’s strategies and decisions and the ability to conclude the strategic review of the business on the anticipated timeframe;
- the Company’s ability to sign and implement new contracts for our solutions;
- the Company’s ability to accurately forecast the costs required to successfully implement new contracts;
- the Company’s ability to accurately forecast the costs necessary to integrate new or acquired businesses, services (including outsourced services) or technologies into the Company’s business;
- the Company’s ability to achieve estimated annualized revenue in backlog in the manner and within the timeframe we expect, which is based on certain estimates regarding the implementation of our services;
- the Company’s ability to anticipate change and respond to emerging trends in the domestic and international markets for healthcare and the impact of the same on demand for the Company’s services;
- the Company’s ability to implement its integrated data and technology solutions platform within the required time frame and expected cost estimates and to develop and enhance this platform and/or other technologies to meet evolving customer and market needs;
- the Company’s ability to renew and/or maintain contracts with its customers under existing terms or restructure these contracts on terms that would not have a material negative impact on the Company’s results of operations;
- the Company’s ability to accurately forecast the Company’s revenues, margins, earnings and net income, as well as any potential charges that the Company may incur as a result of changes in its business and leadership;
- the Company’s ability to accurately forecast performance and the timing of revenue recognition under the terms of its customer contracts ahead of data collection and reconciliation;
- the Company’s ability to accurately forecast enrollment and participation rates in services and programs offered within the Company’s contracts;
- the risks associated with deriving a significant concentration of revenues from a limited number of customers;
- the risks associated with foreign currency exchange rate fluctuations;
- the ability of the Company’s customers to provide timely and accurate data that is essential to the operation and measurement of the Company’s performance;
- the Company’s ability to achieve the contractually required cost savings and clinical outcomes improvements and reach mutual agreement with customers with respect to cost savings, or to achieve such savings and improvements within the time frames it contemplates;
- the risks associated with changes in macroeconomic conditions;
- the risks associated with data privacy or security breaches, computer hacking, network penetration and other illegal intrusions of our information systems or those of third-party vendors or other service providers, which may result in unauthorized access by third parties to customer, employee or Company information or patient health information and lead to enforcement actions, fines and other litigation against the Company;
- the Company’s ability to effectively compete against other entities, whose financial, research, staff, and marketing resources may exceed our resources;
- the Company’s ability to service its debt and remain in compliance with its debt covenants;
- counterparty risk associated with our interest rate swap agreements and foreign currency exchanged contracts;
- the impact of litigation involving the Company and/or its subsidiaries;
- the impact of future state, federal and international legislation and regulations applicable to the Company’s business, including the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010 on the Company’s operations and/or demand for its services; and
- other risks detailed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2015, and other filings with the Securities and Exchange Commission.
The Company undertakes no obligation to update or revise any such forward-looking statements.
Healthways is the largest independent global provider of well-being improvement solutions. Dedicated to creating a healthier world one person at a time, the Company uses the science of behavior change to produce and measure positive change in well-being for our customers, which include employers, integrated health systems, hospitals, physicians, health plans, communities and government entities. We provide highly specific and personalized support for each individual and their team of experts to optimize each participant’s health and productivity and to reduce health-related costs. Results are achieved by addressing longitudinal health risks and care needs of everyone in a given population. The Company has scaled its proprietary technology infrastructure and delivery capabilities developed over 30 years and now serves approximately 68 million people on four continents. Learn more at www.healthways.com.
|CONSOLIDATED STATEMENTS OF OPERATIONS|
|(In thousands, except per share data)|
|Three Months Ended|
|Cost of services (exclusive of depreciation and amortization of |
$10,418 and $9,526, respectively, included below)
|Selling, general and administrative expenses||16,195||15,982|
|Depreciation and amortization||12,746||12,643|
|Restructuring and related charges||5,741||—|
|Equity in income from joint venture||132||—|
|Loss before income taxes||(13,717||)||(4,706||)|
|Income tax expense (benefit)||180||(1,793||)|
|Less: net income attributable to non-controlling interest||312||—|
|Net loss attributable to Healthways, Inc.||$||(14,209||)||$||(2,913||)|
|Loss per share attributable to Healthways, Inc.:|
|Less: comprehensive income attributable to non-controlling |
|Comprehensive loss attributable to Healthways, Inc.||$||(13,261||)||$||(4,590||)|
|Weighted average common shares|
|(1) The impact of potentially dilutive securities for the three months ended March 31, 2016 and 2015 |
was not considered because the effect would be anti-dilutive in each of those periods.
|CONSOLIDATED BALANCE SHEETS|
|March 31,||December 31,|
|Cash and cash equivalents||$||3,094||$||1,870|
|Accounts receivable, net||101,233||108,195|
|Other current assets||4,314||5,230|
|Income taxes receivable||1,293||1,076|
|Deferred tax asset||—||8,209|
|Total current assets||119,991||134,787|
|Property and equipment:|
|Computer equipment and related software||317,918||315,890|
|Furniture and office equipment||19,812||19,776|
|Capital projects in process||16,939||13,676|
|Less accumulated depreciation||(242,546||)||(230,907||)|
|Intangible assets, net||60,480||61,317|
|CONSOLIDATED BALANCE SHEETS|
|(In thousands, except share and per share data)|
|LIABILITIES AND STOCKHOLDERS’ EQUITY|
|March 31,||December 31,|
|Accrued salaries and benefits||21,268||21,620|
|Contract billings in excess of earned revenue||13,967||12,893|
|Current portion of long-term debt||23,007||23,308|
|Current portion of long-term liabilities||6,722||6,204|
|Total current liabilities||164,172||162,190|
|Long-term deferred tax liability||16,328||23,617|
|Other long-term liabilities||28,192||38,238|
|$.001 par value, 5,000,000 shares|
|authorized, none outstanding||—||—|
|$.001 par value, 120,000,000 shares authorized,|
|36,137,666 and 36,079,446 shares outstanding, respectively||36||36|
|Additional paid-in capital||304,121||302,488|
|Retained earnings (deficit)||(4,550||)||9,659|
|Treasury stock, at cost, 2,254,953 shares in treasury||(28,182||)||(28,182||)|
|Accumulated other comprehensive loss||(3,139||)||(4,087||)|
|Total Healthways, Inc. stockholders’ equity||268,286||279,914|
|Total stockholders’ equity||269,372||280,590|
|Total liabilities and stockholders’ equity||$||684,450||$||712,924|
|CONSOLIDATED STATEMENTS OF CASH FLOWS|
|Three Months Ended|
|Cash flows from operating activities:|
|Adjustments to reconcile net loss to net cash flows provided by |
|Depreciation and amortization||12,746||12,643|
|Amortization of deferred loan costs||554||492|
|Amortization of debt discount||1,826||1,726|
|Share-based employee compensation expense||2,427||2,380|
|Equity in income from joint ventures||(132||)||—|
|Deferred income taxes||(191||)||6,067|
|Excess tax benefits from share-based payment arrangements||—||(368||)|
|Decrease in accounts receivable, net||7,471||4,962|
|Decrease in other current assets||1,955||236|
|(Decrease) increase in accounts payable||(1,175||)||4,791|
|Decrease in accrued salaries and benefits||(440||)||(9,937||)|
|Decrease in other current liabilities||(2,013||)||(19,545||)|
|Net cash flows provided by operating activities||7,397||1,831|
|Cash flows from investing activities:|
|Acquisition of property and equipment||(6,450||)||(8,609||)|
|Investment in joint ventures||(453||)||(2,825||)|
|Net cash flows used in investing activities||(7,178||)||(11,720||)|
|Cash flows from financing activities:|
|Proceeds from issuance of long-term debt||131,500||150,850|
|Payments of long-term debt||(136,084||)||(141,086||)|
|Excess tax benefits from share-based payment arrangements||—||368|
|Exercise of stock options||—||1,138|
|Proceeds from non-controlling interest||—||1,377|
|Change in cash overdraft and other||4,600||481|
|Net cash flows provided by financing activities||16||13,128|
|Effect of exchange rate changes on cash||989||(1,252||)|
|Net increase in cash and cash equivalents||1,224||1,987|
|Cash and cash equivalents, beginning of period||1,870||1,765|
|Cash and cash equivalents, end of period||$||3,094||$||3,752|
|RECONCILIATIONS OF NON-GAAP MEASURES TO GAAP MEASURES|
|Reconciliation of Adjusted Net Income (Loss) Per Share Attributable to Healthways, Inc. (“Adjusted |
EPS”) to Net Income (Loss) Per Share Attributable to Healthways, Inc., GAAP Basis (“EPS”)
|Three Months Ended |
|Adjusted EPS, non-GAAP basis (1)||$||(0.08||)||$||(0.01||)|
|EPS (loss) attributable to non-cash interest charges (2)||(0.03||)||(0.03||)|
|EPS (loss) attributable to restructuring charges (3)||(0.10||)||—|
|EPS (loss) attributable to CEO transition-related expenses (4)||(0.01||)||—|
|EPS (loss) attributable to valuation allowance against U.S. deferred tax assets (5)||(0.14||)||—|
|EPS (loss) attributable to non-cash share-based compensation (6)||(0.04||)||(0.04||)|
|EPS (loss), GAAP basis (7)||$||(0.39||)||$||(0.08||)|
(1) Adjusted EPS is a non-GAAP financial measure. The Company excludes EPS (loss) attributable to non-cash interest charges, restructuring charges, CEO transition-related expenses, valuation allowance against U.S. deferred tax assets, and non-cash share-based compensation charges from this measure because of its comparability to the Company's historical operating results. The Company believes it is useful to investors to provide disclosures of its operating results and guidance on the same basis as that used by management. You should not consider Adjusted EPS in isolation or as a substitute for EPS (loss) attributable to Healthways, Inc. determined in accordance with accounting principles generally accepted in the United States.
(2) EPS (loss) attributable to non-cash interest charges consists of pre-tax charges of $1,825,000 and $1,725,000 for the three months ended March 31, 2016 and 2015, respectively, associated with amortization of a debt discount. The tax rate applied to these non-cash interest charges was 39.55%, which represented the combined estimated U.S. federal and state statutory tax rate.
(3) EPS (loss) attributable to restructuring charges consists of pre-tax charges of $5,741,000 for the three months ended March 31, 2016 associated with a Company reorganization and rationalization plan. The tax rate applied to these restructuring charges was 39.55%, which represented the combined estimated U.S. federal and state statutory tax rate.
(4) EPS (loss) attributable to CEO transition-related expenses consists of pre-tax charges of $384,000 for the three months ended March 31, 2016, associated with the cash inducement award granted to our new Chief Executive Officer in 2015. The tax rate applied to these CEO transition-related expenses was 39.55%, which represented the combined estimated U.S. federal and state statutory tax rate.
(5) EPS (loss) attributable to a valuation allowance totals $4,957,000 for the three months ended March 31, 2016, and is the result of the increase in the valuation allowance against certain U.S. deferred tax assets.
(6) EPS (loss) attributable to the non-cash share-based compensation excluding the portion included in restructuring charges consists of pre-tax charges of $2,300,000 and $2,380,000 for the three months ended March 31, 2016 and 2015, respectively. The tax rate applied to these non-cash share-based compensation expenses was 39.55%, which represented the combined estimated U.S. federal and state statutory tax rate.
(7) Figures may not add due to rounding.
|Reconciliation of Adjusted EBITDA|
to Net Income (Loss) Including Non-Controlling Interest, GAAP Basis
|Three Months Ended |
|Adjusted EBITDA, non-GAAP basis(8)||$||11,836||$||14,807|
|Non-cash share-based compensation (9)||(2,300||)||(2,380||)|
|Restructuring charges (10)||(5,741||)||—|
|CEO transition-related expenses (11)||(384||)||—|
|Depreciation and amortization||(12,746||)||(12,643||)|
|Income tax (expense) benefit||(180||)||1,793|
|Net loss including non-controlling interest, GAAP basis||$||(13,897||)||$||(2,913||)|
(8) Adjusted EBITDA is a non-GAAP financial measure. The Company excludes non-cash share-based compensation, restructuring charges, and CEO transition-related expenses from this measure because of its comparability to the Company's historical operating results. The Company believes it is useful to investors to provide disclosures of its operating results and guidance on the same basis as that used by management. You should not consider adjusted EBITDA in isolation or as a substitute for net loss including non-controlling interest determined in accordance with accounting principles generally accepted in the United States.
(9) Non-cash share-based compensation charges consists of pre-tax charges excluding the portion included in restructuring charges of $2,300,000 and $2,380,000 for the three months ended March 31, 2016 and 2015, respectively.
(10) Restructuring charges consists of pre-tax charges of $5,741,000 for the three months ended March 31, 2016 associated with a Company reorganization and rationalization plan.
(11) CEO transition-related expenses consists of pre-tax charges of $384,000 for the three months ended March 31, 2016 associated with the cash inducement award granted to our new Chief Executive Officer in 2015.
Investor Relations Contact: Chip Wochomurka (615) 614-4493 firstname.lastname@example.org